JP2022544272A5 - - Google Patents

Info

Publication number
JP2022544272A5
JP2022544272A5 JP2022508779A JP2022508779A JP2022544272A5 JP 2022544272 A5 JP2022544272 A5 JP 2022544272A5 JP 2022508779 A JP2022508779 A JP 2022508779A JP 2022508779 A JP2022508779 A JP 2022508779A JP 2022544272 A5 JP2022544272 A5 JP 2022544272A5
Authority
JP
Japan
Prior art keywords
diffraction pattern
ray powder
powder diffraction
pattern containing
fumarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544272A (ja
JP7775186B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045847 external-priority patent/WO2021030386A1/en
Publication of JP2022544272A publication Critical patent/JP2022544272A/ja
Publication of JP2022544272A5 publication Critical patent/JP2022544272A5/ja
Priority to JP2025113638A priority Critical patent/JP2025148406A/ja
Application granted granted Critical
Publication of JP7775186B2 publication Critical patent/JP7775186B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508779A 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態 Active JP7775186B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113638A JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962885977P 2019-08-13 2019-08-13
US62/885,977 2019-08-13
PCT/US2020/045847 WO2021030386A1 (en) 2019-08-13 2020-08-12 Salt and crystal forms of an activin receptor-like kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113638A Division JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Publications (3)

Publication Number Publication Date
JP2022544272A JP2022544272A (ja) 2022-10-17
JP2022544272A5 true JP2022544272A5 (https=) 2023-08-21
JP7775186B2 JP7775186B2 (ja) 2025-11-25

Family

ID=72193669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508779A Active JP7775186B2 (ja) 2019-08-13 2020-08-12 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113638A Pending JP2025148406A (ja) 2019-08-13 2025-07-04 アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態

Country Status (14)

Country Link
US (1) US20220281879A1 (https=)
EP (1) EP4013757A1 (https=)
JP (2) JP7775186B2 (https=)
KR (1) KR20220052955A (https=)
CN (2) CN119638704A (https=)
BR (1) BR112022002597A2 (https=)
CA (1) CA3146701A1 (https=)
CO (1) CO2022001450A2 (https=)
IL (1) IL290482A (https=)
JO (1) JOP20220014A1 (https=)
MX (2) MX2022001741A (https=)
TW (1) TWI870440B (https=)
UA (1) UA130650C2 (https=)
WO (1) WO2021030386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311889B (zh) * 2016-04-15 2021-11-16 缆图药品公司 激活素受体样激酶抑制剂
AR112027A1 (es) * 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol

Similar Documents

Publication Publication Date Title
JP2022544272A5 (https=)
JP6966590B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
DK2498610T3 (en) Selective sphingosine-1-phosphate receptor modulators and methods of chiral synthesis
AU2012201453C1 (en) Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2041093B1 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW201706271A (zh) 調節蛋白質激酶之化合物的合成
HUT74609A (en) Substitued aza-indolydene compounds, process for producing them and pharmaceutical compositions containing the same
BG107510A (bg) Карбоксамидни съединения и тяхното използване като антагонисти на човешки 11 cby рецептор
EP3089976A1 (en) Crystalline forms of afatinib di-maleate
JP2022551525A5 (https=)
EP2707364B1 (en) Process for the manufacture of dabigatran etexilate and intermediates thereof
JP2022523368A5 (https=)
EP2619190B1 (en) Substituted oxadiazole compounds and their use as s1p1 agonists
CN101448819A (zh) (5s)-5-[4-(5-氯-吡啶-2-基氧基)-哌啶-1-磺酰基甲基]-5-甲基-咪唑烷-2,4-二酮的新晶体变化形式及其中间体
JP2024521412A5 (https=)
WO2009102226A1 (en) Malonic acid salt of 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- 2,4-thiazolidinedione
JP2024505063A5 (https=)
TW584622B (en) Aromatic amine derivatives having NOS inhibitory effect
JP2024523506A5 (https=)
TWI374136B (en) Water adduct of acetamide moohydrochloride and its crystal
JP2018522945A5 (https=)
CN103193864A (zh) 培哚普利的精氨酸盐的δ晶型、其制备方法和包含它的药物组合物
CN117157294A (zh) 作为蛋白激酶抑制剂的杂环化合物的结晶形式
TW201625582A (zh) 製備吡蟲啉（ｉｍｉｄａｃｌｏｐｒｉｄ）多晶型的方法
JP2024529533A5 (https=)